Biotechnology research company
CovalX AG was originally a Zürich, Switzerland-based company that developed High Mass MALDI detection systems, a mass spectrometric platform for characterizing therapeutic proteins.
Origins.
A spin-off of the Swiss Federal Institute of Technology (ETHZ), CovalX was founded by Ryan Wenzel, Alexis Nazabal, and Urs Matter in 2005 as CovalX GmbH and was converted in January 2007 to AG status to allow additional investors into the company.
In 2011, CovalX founded a wholly owned US subsidiary called CovalX Instruments Incorporated located in the Boston area. They began manufacturing and testing the mass spectrometry instruments based on their proprietary technique as well as sales and support for their hardware products.
CovalX developed and patented a technology platform based on mass spectrometry allowing ultra-fast and direct analysis of protein-protein interactions (PPIs) in solution, called High Mass MALDI.  The technology has been named on many patents including:
Since 2009, CovalX began focusing on analytical service measurements through its growing CRO laboratories and physical locations in Switzerland, France and the US. Today the company specializes in  characterization services for biotherapeutics using its proprietary mass spectrometry solutions. Combining its unique technology platform in combination with other methods such as Hydrogen–deuterium exchange by mass-spectrometry (HDX-MS) and Cross-linking by mass-spectrometry (XL-MS), the company helps scientists worldwide in biotherapeutic development projects. 
Applications:
Notable Citations:
CovalX and its proprietary platform has been cited in many leading publications:
[URL]
[URL]
[URL]
[URL]
Awards.
In April 2006, CovalX received the CTI Start-up Label from the Swiss Confederation's Commission for Technology and Innovation.[2]
References.
 ;templatestyles src="Reflist/styles.css" / ;